|Bid||87.91 x 900|
|Ask||87.29 x 1100|
|Day's Range||87.10 - 88.40|
|52 Week Range||61.05 - 89.93|
|Beta (3Y Monthly)||1.05|
|PE Ratio (TTM)||29.25|
|Earnings Date||Oct 24, 2019|
|Forward Dividend & Yield||0.88 (1.01%)|
|1y Target Est||92.60|
PRA Health (PRAH) expects to enhance position and capabilities in the data and analytics field with the new tool, while simplifying treatment decisions.
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, contraction in gross margin remains a woe.
OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and solid R&D focus. However, operating losses remain a woe.
Zacks.com featured highlights include: Medtronic, Symantec, Target, Popular and Baxter International
Patterson Companies (PDCO) continues to benefit from robust product portfolio, strong prospects in Animal Health unit and strategic buyouts. However, intense competition remains a woe.
Baxter International Inc. (BAX), a leading global medical products company, announced today it has again been named to the Dow Jones Sustainability Indices (DJSI)—the DJSI World and DJSI North America—designations Baxter has received annually since the indices were launched in 1999 and 2005, respectively. Demonstrating a continued focus on its sustainability efforts, Baxter scored in the top five percent of companies assessed within the health care equipment and supplies industry, with leading performance in environmental reporting, strategy to improve access to drugs or products, marketing practices and policy influence.
With this reimbursement approval, Abbott's (ABT) FreeStyle Libre becomes the first sensor-based glucose monitoring system to be listed by any provincial health plan in Canada.
This collaboration is expected to bolster BioSig's (BSGM) commitment toward offering higher quality patient care by introducing innovative technological solutions to medicine.
Walgreens' (WBA) Retail Pharmacy USA division is witnessing comparable prescription growth and also gaining traction from a solid retail prescription market.